Skip to content

JBIO JBIO Net Investment in Lease

Net Investment in Lease at other companies

Vertex Pharmaceuticals logo
Vertex PharmaceuticalsVRTX
Travere Therapeutics, Inc. logo
Travere Therapeutics, Inc.TVTX
AnaptysBio, Inc. logo
AnaptysBio, Inc.ANAB
Avalo Therapeutics logo
Avalo TherapeuticsAVTX
Cullinan Therapeutics, Inc. logo
Cullinan Therapeutics, Inc.CGEM
Vor Biopharma logo
Vor BiopharmaVOR

Other financials

Income statement

See full
Operating income-$43.4M-85.8%
Net income-$40.4M-5.8%
EPS (diluted)-$0.57+95.3%

Balance sheet

See full
Cash & equivalents$55.1M+24.6%
Total debt$808.0K+159%
Total equity$296.5M+455%
Total assets$319.4M+312%

Cash flow

See full
Operating cash flow-$24.1M-28.4%
CapEx$3.0K
Free cash flow-$33.7M

Valuation

See full
Market cap$1.33B+318%
Enterprise value$1.28B

Returns & leverage

See full
Return on equity-132.5%+120pp
Debt / equity
Current ratio14.3×-17.7×

Where this comes from

Reported directly by JBIO in its filing.

Tagged under the XBRL concept us-gaap:OperatingLeaseRightOfUseAsset.

The official record: JBIO’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about JBIO's net investment in lease.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is JBIO's net investment in lease?
JBIO (JBIO) reported net investment in lease of $690K in Q1 2026.
How has JBIO's net investment in lease changed year-over-year?
JBIO's net investment in lease increased by 336.7% year-over-year, from $158K to $690K.
What is the long-term trend for JBIO's net investment in lease?
Over 4 years (2021 to 2025), JBIO's net investment in lease has grown at a 7.6% compound annual growth rate (CAGR), from $542K to $726K.